Drug firm Strides Arcolab today posted a rise of 31.88% in its consolidated net profit at Rs 91 crore for the second quarter ended June 30, 2012, over the same period of previous fiscal.
The company had posted a net profit of Rs 69 crore for the same period of previous fiscal, Strides Arcolab said in a statement.
Net sales of the company stood at Rs 508.29 crore for the second quarter ended June 30, as compared to Rs 581.25 crore during the same period of 2011-12 fiscal.
"It has been a pleasing quarter where both pharma and Agila have delivered superior operating results and additionally addressed key shortages in the US injectables market with specific product launches," Strides Arcolab Limited Vice Chairman & Group CEO Arun Kumar said.
The Bangalore-based firm's division Agila Specialties posted total revenues of Rs 299 crore for the second quarter ended June 30, as against Rs 205 crore in the same period of 2011-12 fiscal.
Shares of Strides Arcolab today closed at Rs 702.75 on the BSE, down 2.12% from its previous close.